Becton, Dickinson and Company (NYSE:BDX) Issues Earnings Results

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43, Zacks reports. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company updated its FY 2025 guidance to 14.300-14.600 EPS.

Becton, Dickinson and Company Price Performance

NYSE:BDX traded up $0.85 during trading hours on Friday, reaching $228.06. 759,064 shares of the company’s stock were exchanged, compared to its average volume of 2,137,293. The business’s 50-day simple moving average is $231.90 and its two-hundred day simple moving average is $234.05. The company has a market capitalization of $66.14 billion, a P/E ratio of 38.41, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.82%. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 597 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $236.51, for a total transaction of $141,196.47. Following the completion of the sale, the executive vice president now owns 5,544 shares in the company, valued at $1,311,211.44. This trade represents a 9.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. This trade represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock valued at $2,210,716 over the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.